Longevity trials: time to change the approach?

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging.

Following the recent clinical trial failures by Unity Biotechnology and resTORbio, Buck professor Brian Kennedy feels that a change in approach is potentially needed.

Longevity.Technology: When we interviewed Kennedy about his new AKG study last week, the conversation occasionally strayed beyond dietary supplements into other areas he’s involved in. Today, we thought we’d share some of those perspectives, including views on aging-related drug development and, more specifically, clinical trials.

“I get the idea that you target aging pathways, but then you try to treat disease because you need to get FDA approval and reimbursement from insurance companies – but if that strategy doesn’t work, we’ve got to stop doing it,” he says. “I think we should actually try to treat aging for a change.”

 


 

“We need to nail down the foundation here and stop giving people excuses why this won’t work … I think we should actually try to treat aging for a change.”

 


 

While Kennedy agrees that effort needs to continue to convince the FDA to recognise aging as a treatable disease, Kennedy also believes that there are alternative approaches that can be employed.

“You don’t need the FDA to approve your trial, you need an IRB to approve your trial,” he says. “From an academic standpoint, as long as you can convince people that the trial is safe, you can use biomarkers and study the effects of these drugs. So I think if we start generating that kind of data, then it’ll be a lot easier to get the FDA on board, and hopefully the rest of the world on board.”

“We need to nail down the foundation here and stop giving people excuses why this won’t work. I’m still optimistic about drugs, but if you develop a drug for A and try to treat B, and then you wonder why it doesn’t work – I’m starting to feel like the strategy may not work that well.”

Brian Kennedy
Brian Kennedy in the lab. Source: Buck Institute

Kennedy points out there’s a big difference between preventing something and treating something, and a lot of the mouse studies pursue a prevention model.

Ovarian Longevity webinar

“We need to use age-appropriate mice for disease studies as well,” he says. “You prevent some disease in young mice and then do a clinical trial to treat the disease in aging humans. Why are we surprised when this does not work very often?”

“It’s a huge change to two big variables there. One, the disease is already happening and two, old people don’t respond the same way young mice do.”

 


 

“There are a lot of questions to answer, but I think that the most advanced clocks are starting to look like good biomarkers.”

 


 

“It would probably reduce the number of positive results you got, which the mouse people don’t necessarily want to do because you can’t publish the papers,” he adds. “But even an expensive mouse study costs $500,000 and a cheap phase three trial in humans is $100 million, so I think we’re being penny wise and pound foolish right now.”

Of course, if companies are going to run trials on aging, then a clearer consensus is needed on the definition of aging, and Kennedy is encouraged by developments in the various clocks that measure biological age.

“There’s a bunch of clocks and we don’t really know how they relate to each other yet, and how specific clocks relate to specific kinds of age-related disease,” he says. “There are a lot of questions to answer, but I think that the most advanced clocks are starting to look like good biomarkers. Some may be better than others but I’m very optimistic about these biomarkers.”

Kennedy believes there are two key factors that should govern what biomarkers are used in trials focused on aging.

“One is cost efficiency – if we’re going to scale something, we need a cheap way to measure aging, we can’t spend $5,000 for everybody,” he says. “And the other is ease of collection. I don’t want to go beyond a blood draw – and I’d rather do it from saliva. Non-invasive stuff is okay, but I’m not doing muscle biopsies and complicated things, because that doesn’t help me develop something that’s scalable to the whole population.”

Image credit: K.Wanvisa / Shutterstock

 

1 COMMENT

Comments are closed.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Unlocking ovarian aging could prolong fertility and delay menopause

Ovarian aging is poorly understood, under-researched and under-invested. We need a radical rethink of how we address fertility and the menopause – it's time...

Fauna closes $9 million to expand drug discovery platform

Leveraging animal genomics to improve human health, Fauna Bio set to expand its comparative genomics platform for novel target drug discovery. Silicon Valley biotech startup...
Nutriop